Honorable Myra Crownover, Chair, House Committee on Public Health
FROM:
Ursula Parks, Director, Legislative Budget Board
IN RE:
HB2675 by Larson (relating to excepting manufacturers engaged in certain commercial research and development from certain provisions of the Texas Controlled Substances Act.), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
The bill would amend the Health and Safety Code to exempt chemical manufacturers engaged in certain specified commercial research and development from certain regulations. It is assumed any costs associated with implementing the provisions of the bill could be absorbed within existing resources and that any revenue loss associated with any associated fee exemptions would not be significant.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.